UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/533,157	12/07/2005	Jean-Jacques Bourguignon		5191	
	26345 7590 12/01/2008 GIBBONS P.C.			EXAMINER	
ONE GATEWA	AY CENTER	KIFLE, BRUCK			
NEWARK, NJ 07102			ART UNIT	PAPER NUMBER	
			1624		
			NOTIFICATION DATE	DELIVERY MODE	
			12/01/2008	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

thibbits@gibbonslaw.com abriggs@gibbonslaw.com IPDocket@gibbonslaw.com

	Application No.	Applicant(s)		
	10/533,157	BOURGUIGNON ET AL.		
Office Action Summary	Examiner	Art Unit		
	Bruck Kifle	1624		
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the o	correspondence address		
A SHORTENED STATUTORY PERIOD FOR REPL'WHICHEVER IS LONGER, FROM THE MAILING D. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tirwill apply and will expire SIX (6) MONTHS from, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. ED (35 U.S.C. § 133).		
Status				
1) ☐ Responsive to communication(s) filed on 19 A 2a) ☐ This action is FINAL . 2b) ☐ This 3) ☐ Since this application is in condition for alloward closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro			
Disposition of Claims				
4) ☐ Claim(s) 37-49 and 55-58 is/are pending in the 4a) Of the above claim(s) 37-49,55 and 57 is/a 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 56 is/are rejected. 7) ☐ Claim(s) 58 is/are objected to. 8) ☐ Claim(s) are subject to restriction and/o	re withdrawn from consideration.			
Application Papers				
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex	epted or b) objected to by the drawing(s) be held in abeyance. Section is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).		
Priority under 35 U.S.C. § 119				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate		

Application/Control Number: 10/533,157 Page 2

Art Unit: 1624

Claims 37-49 and 55-58 are pending in this application.

Election/Restrictions

Applicant's election with traverse of the species of claim 58 in the reply filed on 08/19/08 is acknowledged. The traversal is on the ground that the election of species requirement is not according to the rules. This is not found persuasive because the search and examination of the claims places burden on the office and because this election of species requirement is for search purposes.

The requirement is still deemed proper and is therefore made FINAL.

Claims 39-41 and 48 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to nonelected subject matter.

The elected species has the structure

The elected compound was not found in the search and the search was expanded to embrace the entire scope of formula (1) as claimed in claim 56.

Claim Rejections - 35 USC § 112

Claim 56 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The phrase "and pharmaceutically acceptable salts thereof" is improper Markush

Application/Control Number: 10/533,157

Page 3

Art Unit: 1624

language. Appropriate language, such as, "or a pharmaceutically acceptable salt thereof" is suggested to present what is claimed in alternative form.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim 56 is rejected under 35 U.S.C. 102(b) as being anticipated by Plunkett et al. (Journal of the American Chemical Society (1995), 117(11), 3306-7). The claim reads on compounds 10b and 10f of the reference. See page 3307. These compounds are depicted below for Applicant's convenience. Claims 37, 38, 43 and 44 would also be anticipated.

```
RN 165056-86-0 CAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 1-ethyl-1,3-dihydro-7-hydroxy-5-(3-methoxyphenyl)-3-methyl-, (S)- (9CI) (CA INDEX NAME)
```

Absolute stereochemistry.

```
RN 165056-90-6 CAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 1-ethyl-1,3-dihydro-7-hydroxy-3-methyl-5-[3-(trifluoromethyl)phenyl]-, (S)- (9CI) (CA INDEX NAME)
```

Absolute stereochemistry.

Application/Control Number: 10/533,157

Art Unit: 1624

Claims 37, 38, 42-47, 48, 55 and 57 are withdrawn from consideration because art was found (see MPEP 803.02.)

Applicants are advised of MPEP 803.02 Restriction - Markush Claims [R - 2], fourth and fifth paragraph, where is stated:

"As an example, in the case of an application with a Markush - type claim drawn to the compound C - R, wherein R is a radical selected from the group consisting of A, B, C, D, and E, the examiner may require a provisional election of a single species, CA, CB, CC, CD, or CE. The Markush - type claim would then be examined fully with respect to the elected species and any species considered to be clearly unpatentable over the elected species. If on examination the elected species is found to be anticipated or rendered obvious by prior art, the Markush - type claim and claims to the elected species shall be rejected, and claims to the non - elected species would be held withdrawn from further consideration. As in the prevailing practice, a second action on the rejected claims would be made final." (emphasis added).

On the other hand, should no prior art be found that anticipates or renders obvious the elected species, the search of the Markush-type claim will be extended. If prior art is found that anticipates or renders obvious the Markush-type claim with respect to a non-elected species, the Markush-type claim shall be rejected and claims to the nonelected species held withdrawn from further consideration. The prior art search, however, will not be extended unnecessarily to cover all nonelected species. Should applicant, in response to this rejection of the Markush-type claim, overcome the rejection, as by amending the Markush-type claim to exclude the species anticipated or rendered obvious by the prior art, the amended Markush-type claim will be reexamined. The prior art search will be extended to the extent necessary to determine patentability of the Markush-type claim. In the event prior art is found during the reexamination that anticipates or renders obvious the amended Markush-type claim, the claim will be rejected and the action made final. Amendments submitted after the final rejection further restricting the scope of the claim may be denied entry.

Claim 58 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bruck Kifle whose telephone number is 571-272-0668. The examiner can normally be reached on Mondays-Fridays from 8:30 AM -6:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Bruck Kifle/ Primary Examiner Art Unit 1624

BK

November 21, 2008